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Abstract
Introduction. Around 57% of Hungarian hypertensive patients did not reach the goal blood pressure. According to 
an ESH Newsletter published in 2011, the prevalence of resistant hypertension is 2.9–43%.
Objective. Analysing only the therapy of hypertensive patients of the Hypertension Outpatient Clinic of the Uni­
versity of Szeged, the authors wanted to answer following main questions: How many patients were therapeutically 
resistant according to the definition of resistant hypertension? How many patients were taking 3 or more antihy­
pertensive drugs? How many of these patients reached target SBP values? How many drugs were usually used in 
combination therapy?
Material and methods. Data were retrospectively collected from 01/01/2011 to 31/08/2011 from the electronic 
files of the hypertensive patients. Altogether 310 patients’ data were analysed, of all cases only one visit was taken 
into account. For those patients who visited the Clinic more than once during this period, only the first visit was 
considered. Means of two measurements were calculated. The goal SBP was 140 mmHg.
Results. In this population, 234/310 (76%) patients had resistant hypertension according to the definition (158 ± 
17/97 ± 8 mmHg). Three or more antihypertensive drugs were taken by 257/310 (83%) patients (136 ± 20 mmHg) 
and 134 of them (52% of 257 patients) reached the therapeutic goal. A fourfold combination of antihypertensive 
agents was the most frequent in this population.
Conclusion. It is advised to use multiple drug combinations and it is recommended to spend enough time but not 
longer than necessary to find the most effective combination in every case.
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Background
In Hungary, the number of adult hypertensive pa­
tients (age > 19 year) registered in General Practi­
tioner system had been doubled between 1999 and 
2011 from 1 608 202 to 3 482 000 [1]. Hyperten­
sion (HT) is poorly controlled not only in Hungary, 
but also in Europe and worldwide. As reported in 
a paper based on data from 2005 to 2009, around 
57% of Hungarian hypertensive patients did not 
reach the goal blood pressure (BP) [2]. 
According to the 2013 definition by the European 
Society of Hypertension (ESH) and the European 
Society of Cardiology (ESC), HT is considered as 
therapeutically resistant (RHT) when an appropriate 
lifestyle modification with a triple antihypertensive 
drug combination (a diuretic and two other antihy­
pertensive drugs belonging to different classes, but 
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not necessarily including a mineralocorticoid recep­
tor antagonist) at adequate doses fail to lower systolic 
blood pressure (SBP) and diastolic blood pressure 
(DBP) values to < 140 and 90 mmHg [3]. Patients 
whose BP is controlled, but with 4 or more medica­
tions, are considered to have RHT [4, 5]. In 2007, 
hypertension was defined as resistant or refractory 
to treatment when implementing lifestyle measures 
and at least three drugs (including a diuretic) in 
adequate doses has failed to lower SBP and DBP to 
goal values [6].
The real prevalence of RHT is not known; it varies 
over a wide range depending on the definition of 
RHT and goal BP values used at different data col­
lection locations, the population examined and the 
level of medical screening (etc. work place, general 
practitioner [GP] office, hospital, clinic, HT centre, 
and so on). The prevalence of RHT in GP offices is 
suggested to be less than 5% of the overall HT po­
pulation, while in clinical trials 10–20% and in HT 
centres it may be much more higher [7]. According 
to an ESH Newsletter published in 2011, the preva­
lence of RHT is 2.9–43% [8].
In 2009, the reappraisal of European guidelines 
recommended that SBP should be lowered to < 140/ 
/mmHg in both low to moderate and high risk HT 
patients [9].
Material and methods
The authors analysed data of HT patients registered 
in one of the Hypertension Outpatient Clinics of the 
1st Department of Medicine Nephrology­Hyperten­
sion Centre, University of Szeged, Hungary. Ana­
lysing only the therapy of HT patients, the authors 
wanted to answer following main questions: How 
many patients were taking 3 or more antihyperten­
sive drugs? How many of these patients reached the 
goal SBP values? How many patients were therapeu­
tically resistant according to the definition of RHT? 
How many drugs were usually used in combination 
therapy? In this work, the authors did not investigate 
the possible causes of RHT or any correlations be­
tween the number of drugs and BP values. 
Data were retrospectively collected from 
01/01/2011 to 31/08/2011 from the electronic files 
of the HT patients. Altogether 310 patients’ data 
were analysed; for all cases only one visit was taken 
into account. For those patients who visited the Cli­
nic more than once during this period, only the first 
visit was considered. Blood pressure measurements 
were performed by an OMRON 705IT automatic 
BP monitor. Means of two measurements were cal­
culated. The goal SBP was 140 mmHg, as it was 
recommended in the 2009 reappraisal of European 
guidelines [9].
The authors used only descriptive statistics and 
means ± SD are reported.
Results
The mean age of HT patients was 61.4 ± 14.3 years. 
The mean duration of HT was 14.2 ± 12.0 years. 
Among these 310 HT patients, 115 (37%) were men 
(age 58.2 ± 15.6 years) and 195 (63%) were women 
(age 63.4 ± 13.1 years). By office BP readings the BP 
of 186/310 (60%) patients were in the goal range 
(SBP 124 ± 9 mmHg) and 124/310 (40%) were not 
(SBP 155 ± 17 mmHg).
Among the 310 patients, 45 (15%) had only dia­
betes mellitus (DM) as additional risk factor, type 1 
and type 2 together. Twenty­one (17%) of 124 HT 
patients with undercontrolled BP (149 ± 15/89 ± 
8 mmHg) had DM. 
According to the definition of RHT, altogether 
234/310 (76%) patients had RHT in this popula­
tion. The mean BP of these patients was 158 ± 17/97 
± 8 mmHg. However 257/310 (83%) patients were 
taking 3 or more antihypertensive drugs, and their 
SBP was 136 ± 20 mmHg. The difference (n = 23) 
between 257 and 234 were the patients who were 
prescribed 3 drugs and reached the goal SBP. Alto­
gether 174 patients were taking 4 or more drugs and 
111 of them (47% of 234 RHT patients) had SBP 
< 140/mmHg and 63 (27% of 234 RHT patients) of 
them didn’t reach the goal SBP. 
Among the multiple­drug combinations, 83/310 
(27%) patients were taking 3 antihypertensive drugs, 
65/310 (21%) were taking 4 drugs, 48/310 (15%) 
were taking 5 drugs, 34/310 (11%) were taking 
6 drugs, 20/310 (6%) were taking 7 drugs and 7/310 
(2%) were taking 8 drugs. 
Table I summarizes the different drug combina­
tions and respective SBP values. 
Fifteen patients were on monotherapy; their BP 
was 124 ± 12/79 ± 9 mmHg, and only 1 of them was 
undercontrolled (BP 154/100 mmHg). All the pa­
tients taking 2 drugs (38/310) were in the goal range. 
Table II summarizes the distribution of different 
antihypertensive agents in this population. Forty­one 
patients were not taking any renin­angiotensin sys­
tem inhibitor. Nobody was taking direct renin in­
hibitor. 
Altogether in 123/310 (40%) patients BP was 
undercontrolled; 60% of all the patients were in the 
goal BP range.
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Table I. The different antihypertensive drug combinations and 
systolic blood pressure values (mean ± SD)
Number of drugs  
combined
Patients by goal SBP 
[mmHg]
3 All 136 ± 18 n = 83
Resistant 155 ± 13 n = 60
Controlled 124 ± 9 n = 23
4 All 135 ± 21 n = 65
Resistant 157 ± 19 n = 22
Controlled 124 ± 10 n = 43
5 All 131 ± 14 n = 48
Resistant 150 ± 8 n = 13
Controlled 124 ± 8 n = 35
6 All 145 ± 26 n = 34
Resistant 167 ± 19 n = 16
Controlled 126 ± 11 n = 18
7 All 139 ± 20 n = 20
Resistant 156 ± 17 n = 9
Controlled 126 ± 7 n = 11
8 All 147 ± 21 n = 7
Resistant 161 ± 15 n = 3
Controlled 129 ± 8 n = 4
Discussion
The prevalence of target organ damages such as left 
ventricular hypertrophy, retinopathy, microalbu­
minuria and increased arterial intima­media thick­
ness are 50–100% higher in true RHT compared 
to well­controlled hypertensives. The risk of cardio­
vascular diseases is also 2.5–5 times higher [10, 11].
In Hungary in 2007 the BP of 46% of the non­
dia betic HT population and only 8.5% of the diabet­
ic HT population was in the goal range [12]. During 
the follow­up in the program “Live Under 140/90” 
the proportion of patients reaching the goal BP range 
had been continuously improved: in 2004 it was 
27%, in 2005 — 39%, in 2007 — 44% and in 2010 
— 48–58% [13]. In a Hungarian pilot study enroll­
ing 46 000 HT patients, BP over the goal range most 
frequently was observed in the age groups of 50–59 
(25.4%) and 60–69 (28.7%) years. In this study the 
mean BP over the goal range was 160–179/100–109 
mmHg in 45.6% and 140–159/90–99 mmHg in 
43.8% [14]. 
In this observational study the proportion of 
HT patients with BP in the goal range was quite 
high (60%), but obviously the percentage of pa­
tients prescribed a combination of three or more 
Table II. The distribution of different antihypertensive agents 
(ACEI = angiotensin converting enzyme inhibitor, ARB = an-
giotensin receptor 1 blocker, BB = beta-blocker, DHP-CCB = 
dihydropiridine calcium-channel blocker, I-agonist = imidazoline-
-receptor agonist)
Antihypertensive agents Number of patients
ACEI 179
ARB 90
ACEI + ARB 13
Thiazide diuretics 212
Other diuretics 104









drugs was also very high (83%). Monotherapy was 
sufficient to reach the goal BP only in 4.8%. On 
the other hand, the prevalence of RHT by defi­
nition (and not the prevalence of true RHT) was 
also quite high (76%). These data accords with 
the observations that in specific HT centres the 
prevalence of RHT is higher. Of course not all the 
HTs diagnosed as RHT are true ones. The very first 
thing that is recommended in patients with RHT 
suspicion is to exclude the white coat HT and/or 
white coat effect with a 24­hour ambulatory blood 
pressure monitoring and exclude pseudoresistant 
HT by checking in hospital whether the patient 
is really taking the antihypertensive medications. 
After exclusion these, it is necessary to clear up any 
possible factors interfering with the therapy and 
find possible secondary causes of HT. Finally the 
therapy should be optimized. If BP is still not in 
the goal range after these procedures, than this BP 
is a true resistant one. 
A fourfold combination of antihypertensive agents 
was the most frequent in this population. The most 
frequent drug classes were the ACEIs and/or ARBs, 
the DHP­CCBs and the thiazide diuretics.
In this population, 26 patients (8% of all HT 
patients and 11% of RHT patients) had a secondary 
cause of RHT known at the time of data collection, 
other than DM.  
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Conclusion
In patients with RHT, the prevalence of so called 
identifiable causes is fourfold higher than in non­ 
­RHT patients [15]. Pseudoresistant and secondary 
HT forms are usually tractable, and they can be con­
verted to a controlled form of HT. It is advised to use 
multiple drug combinations and it is recommended 
to spend enough time but not longer than necessary 
to find the most effective combination in every case. 
If there is no any contraindication, a threefold com­
bination of ACEI + DHP­CCB + thiazide diuretic is 
a basic treatment to reach the goal BP. 
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